Trimodulin, a human plasma-derived native polyvalent IgM/IgA-enriched Ig preparation (~ 23% IgM, ~ 21% IgA, and ~ 56% IgG), was previously investigated in 160 patients with sCAP requiring invasive mechanical ventilation (IMV) in the prospective, placebo-controlled, phase II CIGMA trial [12]. The gene discussed is CD40LG; the disease is syringocystadenoma papilliferum.